Skip to content
The Kids Research Institute Australia logo
Donate

No results yet

Search

Research

MEIS proteins as partners of the TLX1/HOX11 oncoprotein

Aberrant expression of the TLX1/HOX11 proto-oncogene is associated with a significant subset of T-cell acute lymphoblastic leukemias...

Research

Parental alcohol consumption and risk of childhood acute lymphoblastic leukemia and brain tumors

Childhood acute lymphoblastic leukemia (ALL) is the most common childhood malignancy and brain tumors (CBTs) are the leading cause of cancer death in...

Research

Parental smoking and risk of childhood brain tumors

Childhood brain tumors (CBT) are the leading cause of cancer death in children, yet their etiology remains largely unknown.

News & Events

Finding new treatments for rare brain cancers in infants

The WA Kids Cancer Centre has secured $1.1 million in funding from the Medical Research Future Fund’s (MRFF) Paediatric Brain Cancer Research Stream 2 to develop more effective and less toxic treatments for rare brain cancers in infants.

News & Events

Adventurers deliver on a promise to help kids with cancer

A state of the art 3D molecular imager that will help researchers monitor how brain tumours grow has been delivered to the Telethon Institute.

Research

Tumor site-directed A1R expression enhances CAR T cell function and improves efficacy against solid tumors

Citation: Sek K, Chen AXY, Cole T, Armitage JD, Tong J, ……… Waithman J, Parish IA, et al. Tumor site-directed A1R expression enhances CAR T cell

Research

IDH-mutant gliomas in children and adolescents - from biology to clinical trials

Gliomas account for nearly 30% of all primary central nervous system (CNS) tumors in children and adolescents and young adults (AYA), contributing to significant morbidity and mortality. The updated molecular classification of gliomas defines molecularly diverse subtypes with a spectrum of tumors associated with age-distinct incidence.

Research

Transcriptional rewiring in CD8+ T cells: implications for CAR-T cell therapy against solid tumours

T cells engineered to express chimeric-antigen receptors (CAR-T cells) can effectively control relapsed and refractory haematological malignancies in the clinic. However, the successes of CAR-T cell therapy have not been recapitulated in solid tumours due to a range of barriers such as immunosuppression, poor infiltration, and tumour heterogeneity.

People

Professor Nick Gottardo

Head of Paediatric and Adolescent Oncology and Haematology, Perth Children’s Hospital; Co-head, Brain Tumour Research Program, The Kids Research Institute Australia

Research

Fetal growth and childhood acute lymphoblastic leukemia: Findings from the childhood leukemia international consortium

The evidence that accelerated fetal growth is associated with a modest increased risk of childhood ALL is strong and consistent with known biological...